Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 17, 2022 at 12:22 am IST
Share
Skinvisible, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.05998 million compared to USD 0.012051 million a year ago. Net loss was USD 0.214519 million compared to USD 0.435505 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.05 compared to USD 0.1 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.
SKINVISIBLE, INC. 